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Abstract
Background The use of fluorescent proteins to label
tumors is revolutionizing cancer research, enabling imag-
ing of both primary and metastatic lesions, which is
important for diagnosis, staging, and therapy. This report
describes the use of fluorescence laparoscopy to image
green fluorescent protein (GFP)-expressing tumors in an
orthotopic mouse model of human pancreatic cancer.
Methods The orthotopic mouse model of human pancre-
atic cancer was established by injecting GFP-expressing
MiaPaCa-2 human pancreatic cancer cells into the pancreas
of 6-week-old female athymic mice. On postoperative day
14, diagnostic laparoscopy using both white and fluores-
cent light was performed. A standard laparoscopic system
was modified by placing a 480-nm short-pass excitation
filter between the light cable and the laparoscope in addi-
tion to using a 2-mm-thick emission filter. A camera was
used that allowed variable exposure time and gain setting.
For mouse laparoscopy, a 3-mm 0 laparoscope was used.
The mouse’s abdomen was gently insufflated to 2 mm Hg
via a 22-gauge angiocatheter. After laparoscopy, the
animals were sacrificed, and the tumors were collected and
processed for histologic review. The experiments were
performed in triplicate.
Results Fluorescence laparoscopy enabled rapid imaging
of the brightly fluorescent tumor in the pancreatic body.
Use of the proper filters enabled simultaneous visualization
of the tumor and the surrounding structures with minimal
autofluorescence. Fluorescence laparoscopy thus allowed
exact localization of the tumor, eliminating the need to
switch back and forth between white and fluorescence
lighting, under which the background usually is so dark-
ened that it is difficult to maintain spatial orientation.
Conclusion The use of fluorescence laparoscopy permits
the facile, real-time imaging and localization of tumors
labeled with fluorescent proteins. The results described in
this report should have important clinical potential.
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Accurate staging is a crucial step in establishing the
appropriate therapeutic approach for patients with pancre-
atic cancer. Curative resection can be achieved in only 10–
20% of newly diagnosed cases [1]. Despite improvements
in computed tomography (CT), magnetic resonance imag-
ing (MRI), and endoscopic ultrasound (EUS), up to 36% of
patients deemed to have resectable disease based on pre-
operative imaging with these techniques are found at
staging laparoscopy to have unresectable disease [2, 3].
Although staging laparoscopy has been demonstrated to
improve the diagnostic yield of peritoneal and liver
metastases otherwise undetectable by preoperative imag-
ing, it is not sufficiently accurate [2–4]. Indeed, studies
examining the accuracy of staging laparoscopy in
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predicting the resectability of peripancreatic tumors
showed false-negative rates of 18–26% [5, 6]. Whereas
some authors report improved accuracy with the addition
of laparoscopic ultrasound [7], others show that false-
negative rates can remain as high as 20% [8]. Given these
problems, efforts to improve the accuracy of staging lap-
aroscopy further are necessary.
Because regular white light can be strongly absorbed
and scattered by normal surrounding tissue, metastatic foci
in the peritoneum and on the liver, which often are small
and flat, can go undetected under standard examination.
The photosensitizer 5-aminolevulinic acid (ALA) and its
metabolite protoporphyrin IX (PPIX) have been used to
fluorescently label a wide range of tumors including
ovarian, renal, and various gastrointestinal malignancies
for fluorescence laparoscopy [9–12]. However, the reso-
lution achieved with this method needs improvement.
Our laboratory pioneered the use of fluorescent proteins
for imaging tumors in mouse models [13] and has devel-
oped this technology for fluorescence-guided surgery [14].
In this study, we applied fluorescent protein-based imaging
to laparoscopy of human pancreatic cancer in an orthotopic
mouse model.
Our study aimed to develop fluorescence laparoscopy
that strongly detects the bright signal from a fluorescently
labeled tumor while still allowing adequate visualization of
the background. Such technology would be instrumental in
future clinical applications of fluorescence laparoscopy,
especially for surgical navigation.
Materials and methods
Cell culture
Human MiaPaCa-2 cells were stably transduced to express
the green fluorescent protein (GFP) as previously described
[15, 16]. These cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) (Gibco-BRL, Grand
Island, NY, USA) supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT, USA), penicillin/streptomy-
cin (Gibco-BRL), sodium pyruvate (Gibco-BRL), sodium
bicarbonate (Cellgro, Manassas, VA, USA), L-glutamine
(Gibco-BRL), and minimal essential medium (MEM)
nonessential amino acids (Gibco-BRL). Cells were incu-
bated at 37C with 5% carbon dioxide (CO2).
Animal care
Female athymic nu/nu nude mice were maintained in a
barrier facility on high-efficiency particulate air (HEPA)-
filtered racks. The animals were fed with autoclaved lab-
oratory rodent diet (Teckland LM-485; Western Research
Products, Orange, CA, USA). All surgical procedures were
performed with the animals under anesthesia using an
intramuscular injection of 0.02 ml of a 50% ketamine, 38%
xylazine, and 12% acepromazine maleate solution. The
animals were sacrificed by injecting 0.05 ml of the same
solution, followed by cervical dislocation. All animal
studies were approved by the UCSD Institutional Animal
Care and Use Committee (IACUC) and conducted in
accordance with the principles and procedures outlined in
the National Institutes of Health (NIH) Guide for the Care
and Use of Animals.
Orthotopic pancreatic cancer model
MiaPaCa-2-GFP cells were harvested by trypsinization and
washed three times with serum-free medium. Viability was
verified to be greater than 95% using the Vi-Cell XR
automated cell viability analyzer (Beckman Coulter, Brea,
CA, USA). The cells were resuspended at concentrations of
1 9 106 per 20 ll of serum-free medium and placed on ice
before surgery.
Orthotopic implantation was performed in 6-week-old
female nude mice by first making a 6- to 10-mm transverse
incision on the left flank of the mouse through the skin and
peritoneum. The tail of the pancreas then was exposed
through this incision. Pancreatic cancer cells (1 9 106)
were injected into the pancreatic tail, which was subse-
quently returned into the abdomen. The incision was closed
in two layers using 6.0 Ethibond nonabsorbable suture
(Ethicon Inc., Somerville, NJ, USA).
Fluorescence laparoscopy
An ideal fluorescence laparoscope should possess the fol-
lowing properties: first, it should maximize the fluores-
cence signal of the tumor to facilitate its easy and rapid
imaging. Second, it should provide a clear view of the
background and surrounding tissues to allow maintenance
of spatial orientation. This second aspect has special
importance when the scope is used in a therapeutic rather
than a strictly diagnostic capacity. To achieve these crite-
ria, we modified a standard laparoscopic system in the
following manner (Fig. 1): the excitation light source, a
300-W Xenon lamp (Stryker, Kalamazoo, MI, USA), was
filtered by a 480-nm interference short-pass filter. To avoid
heat damage to the filter, this excitation filter was placed at
the end of the optical fiber, which delivers the light to the
laparoscope. An emission filter, whose selection is descri-
bed below, was also placed between the laparoscope and
the camera. A MultiCam 310C camera (UVP, Upland, CA,
USA), which allows variable exposure time and gain set-
ting in the controlling software (VisionWorks LS, UVP),
was used. To meet our objective of dual functionality
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through live video, the exposure time was set at 110 ms,
and the gain was set to 97.
The emission filter was chosen from three possible
options that match in the emission band of GFP at 520 nm
(a 515-nm long-pass interference filter, a Schott OG515
glass filter, or a Schott GG495 glass filter) after the
absorption spectra of their respective combinations with the
480-nm excitation filter had been obtained. The background
transmission ratio was calculated from summing the
absorption spectra of the filter combinations and translating
the combined absorbance (A) to transmission (10-A). The
results indicated that the 2-mm-thick Schott GG495 glass
filter was the preferred emission filter (see Results section).
This particular filter was preferable because, unlike inter-
ference filters that typically have optical density (OD) 4 (i.e.
leaking only 10-4 of light outside the allowed spectrum) or
higher capability in blocking the background, it allows 1%
of the background to leak through. This design affords
visualization of the nonfluorescent tissue for navigation
while enhancing the fluorescence signal of the tumor.
Mouse laparoscopy
Two weeks after orthotopic implantation of the MiaPaCa-
2-GFP cells, the mice were anesthetized before laparos-
copy. Under sterile conditions, a 22-gauge angiocatheter
was gently introduced into the abdominal cavity at an angle
to avoid injury to the underlying bowel. The catheter was
secured to the abdominal wall with a suture and connected
to the insufflation tubing of the laparoscopic tower. Insuf-
flation was first initiated at 1 mm Hg, then augmented to a
final pressure of 2 mm Hg.
Next, a small incision was made higher up in the
abdomen, through which a 3-mm 0 Karl-Storz laparo-
scope (Karl-Storz GmbH & Co., Tuttlingen, Germany) was
introduced. A purse-string suture was placed around this
incision to prevent its widening and to maintain proper
insufflation (Fig. 2). Due to the limitations presented by the
small size of the mice, no other ports were placed. At
termination of laparoscopy, the mice were sacrificed for
tumor collection.
Tissue histology
At necropsy, the fluorescent tumor was collected, placed in
Bouin’s solution, sectioned, and subsequently placed on
slides for histology with hematoxylin and eosin (H&E)
staining. The slides were reviewed by a pathologist to
confirm the identity of the fluorescent lesion.
Data processing
Images obtained during laparoscopy were not processed in
any way. Representative frames are presented. Histology
images were processed for brightness and contrast using
Photoshop Element 4 (Adobe Systems Inc., San Jose, CA,
USA).
Results
Two weeks after orthotopic implantation of MiaPaCa-2-
GFP human pancreatic cancer cells, female athymic mice
were anesthetized before undergoing a diagnostic laparos-
copy under both white and fluorescence modes. By this
time, all the animals had tumors that measured approxi-
mately 1 cm in diameter. For fluorescence laparoscopy,
insufflation to 2 mm Hg allowed ample distention of the
abdominal wall to enable adequate visualization and nav-
igation within the abdomen of the mice.
Fig. 1 Fluorescence
laparoscope for visualization
and localization of green
fluorescent protein (GFP)-
labeled tumors in mice. A
laparoscopic tower was
modified to achieve a
fluorescence light mode that
would permit detection of
fluorescence signals while still
allowing visualization of the
background tissue. A 480-nm
short-pass filter was placed
between the light cable and the
laparoscope. A GG495 glass
filter was placed between the
laparoscope and a camera that
controls exposure time and gain.
These parameters were set to
110 ms and 97, respectively, for
the purpose of our experiment
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Because peak excitation for the GFP occurs at 488 nm, a
480-nm short-pass excitation filter was used. Three dif-
ferent emission filters were tested that all achieved excel-
lent and equivalent background suppression in the emission
band of GFP at 520 nm, which serves to create the best
contrast between fluorescence and background. Addition-
ally, the distinguishing advantage of an ideal emission filter
would be preservation of sufficient contrast while enough
of the background is allowed to leak through to maintain
spatial orientation.
Spectral analysis of combinations of the 480-nm exci-
tation filter with each of the three emission filters tested
demonstrated that at wavelengths shorter than 520 nm, the
GG495 filter allowed the best transmission of background
light while achieving the same degree of contrast between
fluorescence and background (Fig. 3).
When either the OG515 or 515LP emission filters were
used, the fluorescent tumor became visible. However, the
background became so darkened that it was impossible to
pinpoint the location of the tumor (Fig. 4a, b). To visualize
the surrounding tissue and locate the tumor, the laparo-
scope would have to be switched back and forth between
white and fluorescence modes. The GG495 filter overcame
this problem (Fig. 4c). The combination of the Xenon
lamp, the 480-nm short-pass excitation filter, and the
GG495 long-pass emission filter produced a spectrum that
not only provided a sufficient background but also resulted
in proper color balance. By using a camera with adjustable
exposure time and gain, these two parameters can be
optimized to compensate for the lack of intensity from the
Xenon lamp.
For the purpose of our experiment, an exposure time of
110 ms and a gain of 97 afforded clear visualization of
both the fluorescent tumor and the surrounding structures.
The increasing noise due to increased gain was dynamic
and did not interfere with the diagnostic purpose. The
exposure time, however, had to be kept shorter than the
time frame of typical biologic reactions, such as the
interval of heart beats, to remain useful for navigation.
With this proper combination of instruments and light
parameters, fluorescence laparoscopy permitted rapid and
easy identification of the fluorescent tumor while still
permitting visualization of the surrounding tissue. In fact,
the GFP-expressing tumor was sufficiently bright to enable
its instant localization (Fig. 5). Navigation through the
abdominal cavity under this fluorescent mode was
straightforward because we were able to maintain an ade-
quate view of the surrounding structures.
At termination of laparoscopy, the mice were sacrificed,
and the identified lesions were collected for histology. The
use of H&E stain confirmed that these fluorescent lesions
were indeed pancreatic adenocarcinoma tumors (Fig. 6).
Discussion
Staging laparoscopy has a demonstrated role in the evalu-
ation of certain gastrointestinal malignancies, including
gastric cancer [17] and pancreatic cancer [4]. The detection
of a cancerous lesion on the surface of the peritoneum or
the liver in a minimally invasive way can spare the patient
with metastatic disease from an unnecessary and costly
celiotomy, fraught with potential complications. Unfortu-
nately, standard laparoscopy can bear false-negative rates
as high as 26%, underscoring the need to improve its
diagnostic yield [6].
Several authors have previously described the applica-
tion of fluorescence technology to this endeavor, relying on
ALA-induced PPIX to highlight potentially malignant
lesions [9–12]. Although the results have been impressive,
ALA is not cancer-specific and can at times fluorescently
label benign lesions [10, 11]. Labeling that is cancer-
Fig. 2 Mouse laparoscopy. To achieve laparoscopy in the mouse, a
22-gauge angiocatheter was inserted into the abdominal cavity and
attached to the insufflation tubing of the laparoscopic tower. The
abdomen was insufflated to 2 mm Hg, and a 3-mm 0 laparoscope
was introduced into the abdomen for diagnostic purposes. The
laparoscope was secured with a purse-string suture
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Fig. 3 Spectral analysis of filter combinations of the 480-nm
excitation filter and three potential emission filters. At 520 nm within
the emission band of green fluorophores (green fluorescent protein
[GFP], Alexa-488, fluorescein), all three combinations performed
equally well. However, at shorter wavelengths, they differed signif-
icantly, resulting in different background transmission capabilities.
The 515-nm long-pass interference filter almost completely blocked
background transmission, whereas the two glass filters (GG495 and
OG515) achieved a more desirable signal-to-background ratio. The
background ratio of GG495 was appropriate for generating a non zero
background for navigation and signal detection without fully saturat-
ing the charge-coupled device (CCD) which can cause loss of detail
Fig. 4 Fluorescence signal from a green fluorescent protein (GFP)-
expressing pancreatic tumor as seen with three different emission
filters. A When an interference filter was used, the fluorescence signal
was strong, but the background was almost completely blocked out
and appeared nearly uniformly black. B Using the OG515 glass filter
instead, slightly more background came through, although it was still
insufficient for navigation. Also, the color balance with this filter was
not optimal. C The use of the GG495 glass filter achieved a good
color balance and adequate visualization of the background while
maintaining good signal-background contrast
Fig. 5 Fluorescence laparoscopy at different angles and distances in
a mouse with orthotopically implanted green fluorescent protein
(GFP)-expressing pancreatic cancer. Due to the fluorescence of the
tumor, a green glow (arrow) was quickly detected at entry into
the abdominal cavity (A) which easily led to the exact localization of
the tumor within the body of the pancreas (B, C). The fluorescence
signal of the tumor was easily seen. The surrounding structures,
including the bowel and its vessels remained clearly visible as well
permitting facile navigation within the abdominal cavity without the
need to flip between a fluorescence mode and a white light mode
52 Surg Endosc (2011) 25:48–54
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specific and selective could be of great value. Furthermore,
the fluorescence signal elicited from PPIX can be intrin-
sically weak. In one study using ALA in neurosurgery,
fluorescence of the glioma evaluated was only 25% greater
than that of the normal brain tissue and was surpassed by
that of the periosteum and skin [18]. This weakness of the
fluorescence signal, when translated to the laparoscopic
setting, would require a fluorescence mode that inevitably
darkens the background significantly.
Likewise, Adusumilli et al. [19] have previously
described and used GFP-guided fluorescence laparoscopy
for tumor detection using a replication-competent herpes
simplex virus to label the tumors with GFP. In that study,
the investigators alternated between the use of white light
and fluorescence light to spatially localize the tumor. This
could pose potential disadvantages, especially if careful
surgical navigation is required around critical structures.
As such, the value of fluorescence laparoscopy is dimin-
ished when the strength of the fluorescent signal is
enhanced at the expense of the visibility of the background.
With this in mind, we developed a laparoscopic fluores-
cence mode that allows facile and rapid identification and
localization of a fluorescently labeled tumor while still
maintaining adequate visualization of the surrounding tissue.
The clear advantage that it offers is the ability to navigate
within the abdominal cavity without losing spatial orienta-
tion, something that the standard ultraviolet light described
in previous fluorescence laparoscopy reports cannot do.
Two main issues govern the efficacy of fluorescence
laparoscopy. First, the right filter sets must be used to
permit proper excitation of the fluorescent tumor and
detection of its signal while still allowing visualization of
the surrounding tissue for navigation. Second, even with
the proper filter set in place, the exposure time of the
fluorophore to the exciting light must be lengthened to
enhance the brightness of the fluorescence signal, which
would otherwise be rather weak. In addition, the gain must
be adjusted to optimize visualization of both the tumor and
surrounding tissues. By modifying a standard laparoscope
with a set of excitation and emission filters that allow some
background leakage of bright light without compromising
signal-background contrast and by adjusting camera-con-
trolled parameters such as exposure time and gain, we were
able to quickly and easily detect a GFP-expressing tumor in
the body of the mouse’s pancreas.
Although we have chosen to use pancreatic cancer cells
previously engineered to highly express GFP in vivo for the
purpose of this study, it must be pointed out that a number
of methods have been used to fluorescently label intrinsic,
existing tumors. Our laboratory has pioneered several of
these techniques, including the use of antibodies against
tumor antigens such as carcinoembryonic antigen (CEA) or
CA19-9 to deliver fluorophores to pancreatic cancer lesions
[20, 21]. Because CEA and CA19-9 are expressed in up to
98% and 91% of pancreatic ductal adenocarcinomas,
respectively [22], the clinical application of fluorophore-
conjugated antibodies directed against them should allow
identification of almost all pancreatic adenocarcinoma
lesions. Fluorescence laparoscopy of tumors labeled with
GFP or fluorescent antibodies should be a powerful tool in
the diagnosis and staging of pancreatic cancer.
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